Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia

NCT05179226 | Recruiting Phase 3 DMC FDA Drug

• 2 other identifiers: P-Monofer-PED-01U1111-1266-9073
• Study Type: interventional
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

Several clinical trials have been reported for ferric derisomaltose where it has been shown to be well tolerated and to improve markers of IDA. All clinical trials with ferric derisomaltose have been performed in adults, however, IDA is not specific to the adult population. In fact, children are likely to develop IDA due to their rapid growth. The aim in this trial is to evaluate the efficacy and safety of intravenous (IV) ferric derisomaltose in children 0 to \<18 years of age with IDA due to NDD-CKD or with IDA who are intolerant or unresponsive to oral iron . The subjects will receive ferric derisomaltose/iron isomaltoside 1000 (Monoferric®/Monofer®), at single doses of 10 mg/kg or 20 mg/kg with a maximal dose of 1000 mg. 24 subjects will be part of a PK assessment, meaning that more blood samples will be drawn within the first week after treatment. The blood samples will be used for analysis of the amount of total iron in the blood from treatment is given to day 7. For the individual subject, duration of the trial will be approximately 10 weeks (including a 14-day screening period) and each subject will attend 6-9 visits. Subjects who will be included in the PK assessments will attend 8 (subjects age 6 to \<12 years old and 0 to \<6 years old) or 9 (subjects age 12 to \<18 years old) visits, while the other subjects will attend 6 visits.

Conditions

Iron Deficiency, Anaemia in Children

Outcome Measures

Primary Outcomes (1)

• Incidence of subjects with a Hb increase of ≥1 g/dL (NDD-CKD) or 2 g/dL (intolerant or unresponsive to oral iron). Measurement by bloodsample.

  Hb (g/dL), measurement by bloodsample analysis

  From baseline at any time from week 1 to week 8

Secondary Outcomes (13)

• Time to increase Hb ≥1 g/dL (NDD-CKD) or 2 g/dL (intolerant or unresponsive to oral iron). Measurement by bloodsample.

  From baseline at any time from week 1 to week 8

• Incidence of subjects who achieve a serum (s-) ferritin of ≥100 ng/mL. Measurement by bloodsample.

  At weeks 1, 2, 4, and 8

• Incidence of subjects who achieve a TSAT of ≥35 % (NDD-CKD) or ≥20 % (intolerant or unresponsive to oral iron). Measurement by bloodsample.

  At weeks 1, 2, 4, and 8

• Total iron PK parameters: AUC0-∞

  From baseline to day 7

• Total iron PK parameters: AUC0-t

  From baseline to day 7

Study Arms (1)

Ferric Derisomaltose

EXPERIMENTAL

All subjects (a total of 200) will be treated with Ferric Derisomaltose. 12 subjects (half of the 24 subjects participating in the PK-part of the trial) will be treated with 10mg/kg while the remaining subjects will be treated with 20 mg/kg. .

Drug: Ferric Derisomaltose

Interventions

Ferric Derisomaltose DRUG

All subjects will be treated with Ferric derisomaltose 20 mg/kg at baseline visit except for 12 subjects included in the PK-group, who will be treated with 10 mg/kg

Also known as: Monofer®, Monoferric®

Ferric Derisomaltose

Eligibility Criteria

• Age: Up to 17 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Subjects \<18 years
• Informed consent and child assent, as age-appropriate, obtained before any trial- related activities and willingness to participate. LAR of the subject must sign and date the ICF (according to local requirements). The child must sign and date the CAF or provide oral assent, if required according to local requirements
• IDA caused by different etiologies such as gastrointestinal disease, NDD-CKD, or other conditions leading to IDA
• Hb concentration less than the 5th percentile for age and sex-specific reference range (Appendix B)
• Subjects with NDD-CKD (a) or who are intolerant or unresponsive to oral iron (b):
• a) Subjects with NDD-CKD:
• TSAT ≤35 % or s-ferritin \<100 ng/mL
• Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m2
• If on ESA, receiving stable ESA regimen defined as dose adjustments no more than
• ± 20 % for ≥8 weeks prior to screening
• b) Subjects with documented history of intolerance or unresponsiveness to oral iron therapy for at least one month prior to trial enrolment.
• TSAT ≤20 % or s-ferritin \<100 ng/mL

You may not qualify if:

• Anemia caused by factors other than IDA according to Investigator's judgment
• S-ferritin \>600 ng/mL
• Hb ≤5.0 g/dL
• Iron overload or disturbances in utilization of iron (e.g. hemochromatosis and hemosiderosis)
• ALAT and/or ASAT \>2 times upper limit of normal (e.g. decompensated liver cirrhosis or active hepatitis)
• Pregnant or nursing female subjects. In order to avoid pregnancy, female subjects of childbearing potential have to use adequate contraception (e.g. intrauterine devices, hormonal contraceptives, or double barrier method) or be abstinent during the whole trial period and 7 days after the last dosing. Childbearing potential refers to all female subjects ≥12 years old or \<12 years old who have started menstruating
• Previous serious hypersensitivity reactions to any IV iron compounds including ferric derisomaltose
• Received an investigational drug within 30 days prior to screening
• Treatment with IV iron within 10 days prior to screening
• Treatment with blood transfusion, radiotherapy, chemotherapy or other drugs that suppress the bone marrow, and drugs which have anemia as side effect within 30 days prior to screening
• Planned elective surgery (or planned surgery during the trial period) where significant blood loss is expected within the last 30 days prior to screening
• Any non-viral infection (non-viral infection that has been fully treated before the baseline visit is accepted)
• Any other laboratory abnormality, medical condition, or psychiatric disorders which, in the opinion of the Investigator, will put the subject's disease management at risk or may result in the subject being unable to comply with the trial requirements

Sponsors & Collaborators

• Pharmacosmos A/S: lead

Study Sites (1)

Pharmacosmos Investigational Site

Miami, Florida, 33142, United States

RECRUITING

MeSH Terms

Conditions

Iron Deficiencies

Interventions

ferric derisomaltose

Condition Hierarchy (Ancestors)

Iron Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Central Study Contacts

Pharmacosmos A/S Clinical and Non-clinical Research

CONTACT

+4559485959; info@pharmacosmos.com

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: The study includes a PK-part. 24 subjects will be part of a PK assessment and have total- iron PK-parameters measured 7 or 8 times between baseline visit and week 1.

Study Record Dates

• First Submitted: November 16, 2021
• First Posted: January 5, 2022
• Study Start: November 28, 2022
• Primary Completion: April 30, 2026
• Study Completion: April 30, 2026
• Last Updated: April 14, 2026

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)